Literature DB >> 12662160

Plasma phospholipid transfer protein activity and small, dense LDL in type 2 diabetes mellitus.

K C B Tan1, S W M Shiu, Y Wong.   

Abstract

BACKGROUND: Phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) remodel circulating lipoproteins and play a role in the antiatherogenic reverse cholesterol transport pathway. The present study determined whether abnormalities in the LDL subfraction pattern in type 2 diabetic patients were related to changes in lipid transfer proteins.
METHODS: Low-density lipoprotein (LDL) subfractions were measured by density gradient ultracentrifugation and plasma PLTP and CETP activities by radiometric assays in 240 diabetic patients and 136 controls.
RESULTS: The diabetic patients had lower LDL-I (P < 0.001) and higher LDL-III concentrations than the controls (P < 0.001). Plasma PLTP activity was increased (P < 0.001) whereas no significant differences were seen in CETP activity. In the diabetic patients, small, dense LDL-III correlated with plasma triglyceride (r = 0.18, P < 0.01), HDL (r = -0.14, P < 0.05), PLTP (r = 0.29, P < 0.001) and CETP activity (r = 0.15, P < 0.05). Linear regression analysis showed that plasma PLTP activity, triglyceride and age were the major determinants of LDL-III concentration (r2 = 28%, P < 0.001). The univariate relationship between CETP and LDL-III was no longer significant after adjusting for PLTP activity.
CONCLUSIONS: The increase in plasma PLTP activity was independently associated with small, dense LDL concentrations in type 2 diabetes. Hence, elevated PLTP activity might have both antiatherogenic and pro-atherogenic potential in these patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12662160     DOI: 10.1046/j.1365-2362.2003.01132.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus.

Authors:  R de Vries; G M Dallinga-Thie; A J Smit; B H R Wolffenbuttel; A van Tol; R P F Dullaart
Journal:  Diabetologia       Date:  2005-12-23       Impact factor: 10.122

2.  Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease.

Authors:  Erdal Cavusoglu; Jonathan D Marmur; Sandeep Chhabra; Mohammad R Hojjati; Sunitha Yanamadala; Vineet Chopra; Calvin Eng; Xian-Cheng Jiang
Journal:  Atherosclerosis       Date:  2015-02-16       Impact factor: 5.162

3.  Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Authors:  Ali Javaheri; Ahmed Diab; Lei Zhao; Chenao Qian; Jordana B Cohen; Payman Zamani; Anupam Kumar; Zhaoqing Wang; Christina Ebert; Joseph Maranville; Erika Kvikstad; Michael Basso; Vanessa van Empel; A Mark Richards; Robert N Doughty; Ernst Rietzschel; Karl Kammerhoff; Joseph Gogain; Peter Schafer; Dietmar A Seiffert; David A Gordon; Francisco Ramirez-Valle; Douglas L Mann; Thomas P Cappola; Julio A Chirinos
Journal:  Circ Heart Fail       Date:  2022-08-09       Impact factor: 10.447

4.  Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.

Authors:  Dick C Chan; P Hugh R Barrett; Gerald F Watts
Journal:  Clin Biochem Rev       Date:  2004-02

Review 5.  A Systems Biology Overview on Human Diabetic Nephropathy: From Genetic Susceptibility to Post-Transcriptional and Post-Translational Modifications.

Authors:  Francesca Conserva; Loreto Gesualdo; Massimo Papale
Journal:  J Diabetes Res       Date:  2015-12-20       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.